Literature DB >> 19744690

Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.

Feng Gao1, Richard M Scearce, S Munir Alam, Bhavna Hora, Shimao Xia, Julie E Hohm, Robert J Parks, Damon F Ogburn, Georgia D Tomaras, Emily Park, Woodrow E Lomas, Vernon C Maino, Susan A Fiscus, Myron S Cohen, M Anthony Moody, Beatrice H Hahn, Bette T Korber, Hua-Xin Liao, Barton F Haynes.   

Abstract

The extraordinarily high level of genetic variation of HIV-1 env genes poses a challenge to obtain antibodies that cross-react with multiple subtype Env glycoproteins. To determine if cross-reactive monoclonal antibodies (mAbs) to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced, we immunized mice with wild-type or consensus HIV-1 Env proteins and characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env proteins by ELISA and Western blot analysis. Two mAbs (3B3 and 16H3) cross-reacted with all tested Env proteins, including SIVcpzUS Env. Surface plasmon resonance analyses showed both 3B3 and 16H3 bound Env proteins with high affinity. However, neither neutralized primary HIV-1 pseudoviruses. These data indicate that broadly reactive non-neutralizing monoclonal antibodies can be elicited, but that the conserved epitopes that they recognize are not present on functional virion trimers. Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744690      PMCID: PMC2785033          DOI: 10.1016/j.virol.2009.07.041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Deceptive imprinting and immune refocusing in vaccine design.

Authors:  Gregory J Tobin; Jessie D Trujillo; Ruth V Bushnell; George Lin; A Ray Chaudhuri; Jinxue Long; Jose Barrera; Lindomar Pena; Marvin J Grubman; Peter L Nara
Journal:  Vaccine       Date:  2008-10-11       Impact factor: 3.641

4.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

6.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates.

Authors:  S A Lee; R Orque; P A Escarpe; M L Peterson; J W Good; E M Zaharias; P W Berman; H W Sheppard; R Shibata
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

8.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  21 in total

1.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

2.  HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.

Authors:  Philip R Tedbury; Mariia Novikova; Ayna Alfadhli; Yuta Hikichi; Ioannis Kagiampakis; Vineet N KewalRamani; Eric Barklis; Eric O Freed
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

3.  IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation.

Authors:  Dominik Hotter; Matteo Bosso; Kasper L Jønsson; Christian Krapp; Christina M Stürzel; Atze Das; Elisabeth Littwitz-Salomon; Ben Berkhout; Alina Russ; Sabine Wittmann; Thomas Gramberg; Yue Zheng; Laura J Martins; Vicente Planelles; Martin R Jakobsen; Beatrice H Hahn; Ulf Dittmer; Daniel Sauter; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2019-06-04       Impact factor: 21.023

4.  Generation of random mutant libraries with multiple primers in a single reaction.

Authors:  Xiaozhi Lu; Bhavna Hora; Fangping Cai; Feng Gao
Journal:  J Virol Methods       Date:  2010-03-31       Impact factor: 2.014

5.  Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.

Authors:  Jae-Sung Yu; Hua-Xin Liao; Jamie Pritchett; Cindy Bowman; Callie Vivian; Robert Parks; Shi-Mao Xia; Melissa Cooper; Wilton B Williams; Mattia Bonsignori; Steven G Reed; Meng Chen; Nathan Vandergrift; Charles M Rice; Barton F Haynes
Journal:  J Virol Methods       Date:  2017-08-31       Impact factor: 2.014

6.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

Review 7.  Monoclonal antibody-based candidate therapeutics against HIV type 1.

Authors:  Weizao Chen; Dimiter S Dimitrov
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

8.  HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.

Authors:  M Anthony Moody; Nicole L Yates; Joshua D Amos; Mark S Drinker; Joshua A Eudailey; Thaddeus C Gurley; Dawn J Marshall; John F Whitesides; Xi Chen; Andrew Foulger; Jae-Sung Yu; Ruijun Zhang; R Ryan Meyerhoff; Robert Parks; Julia Cavanaugh Scull; Lu Wang; Nathan A Vandergrift; Joy Pickeral; Justin Pollara; Garnett Kelsoe; S Munir Alam; Guido Ferrari; David C Montefiori; Gerald Voss; Hua-Xin Liao; Georgia D Tomaras; Barton F Haynes
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

9.  A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.

Authors:  Yuxin Chen; Michael Vaine; Aaron Wallace; Dong Han; Shengqin Wan; Michael S Seaman; David Montefiori; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

10.  Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk.

Authors:  Genevieve G Fouda; Frederick H Jaeger; Joshua D Amos; Carrie Ho; Erika L Kunz; Kara Anasti; Lisa W Stamper; Brooke E Liebl; Kimberly H Barbas; Tomoo Ohashi; Martin Arthur Moseley; Hua-Xin Liao; Harold P Erickson; S Munir Alam; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.